Health Catalyst Q2 2024 Adj. EPS $0.12 Beats $0.08 Estimate, Sales $75.902M Beat $75.005M Estimate
Portfolio Pulse from Benzinga Newsdesk
Health Catalyst (NASDAQ:HCAT) reported Q2 2024 adjusted EPS of $0.12, beating the estimate of $0.08 by 50%. Sales were $75.902M, surpassing the $75.005M estimate and showing a 3.67% increase from the same period last year.
August 07, 2024 | 8:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Health Catalyst (NASDAQ:HCAT) reported Q2 2024 adjusted EPS of $0.12, beating the estimate of $0.08 by 50%. Sales were $75.902M, surpassing the $75.005M estimate and showing a 3.67% increase from the same period last year.
The significant beat on EPS and the slight beat on sales, along with year-over-year growth, are likely to positively impact HCAT's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100